Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo
- PMID: 17392488
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase is the rate-limiting enzyme in the mevalonate pathway that provides essential intermediates for the membrane anchorage and biologic functions of growth-related proteins. Contrary to preclinical studies showing the growth-suppressive activity of statins, competitive inhibitors of HMG CoA reductase, clinical application of statins in cancer is precluded by their lack of activity at levels prescribed for the prevention of cardiovascular disease and by their dose-limiting toxicities at high doses. The dysregulated and elevated HMG CoA reductase activity in tumors retains sensitivity to the isoprenoid-mediated posttranscriptional down-regulation, an action that complements the statin-mediated inhibition and may lead to synergistic impact of blends of isoprenoids and lovastatin on tumor HMG CoA reductase activity and consequently tumor growth. d-gamma- and d-delta-tocotrienols, vitamin E isomers containing an isoprenoid moiety, and lovastatin-induced concentration-dependent inhibition of the 48-hr proliferation of murine B16 melanoma cells with IC50 values of 20 +/- 3, 14 +/- 3, and 1.5 +/- 0.4 microM respectively. A blend of lovastatin (1 microM) and d-gamma-tocotrienol (5 microM) totally blocked cell growth, an impact far exceeding the sum of inhibitions induced by lovastatin (12%) and d-gamma-tocotrienol (8%) individually. Synergistic impact of these two agents was also shown in human DU145 prostate carcinoma and human A549 lung carcinoma cells. C57BL6 mice were fed diets supplemented with 12.5 mg lovastatin/kg body weight, 62.5 mg d-delta-tocotrienol/kg body weight, or a blend of both agents for 22 days following B16 cell implantation; only the latter had significantly lower tumor weight than those with no supplementation. Co-administration of isoprenoids that posttranscriptionally down-regulate tumor reductase may lower the effective dose of statins and offer a novel approach to cancer chemo-prevention and/or therapy.
Similar articles
-
d-δ-Tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells.Pancreas. 2009 May;38(4):e124-36. doi: 10.1097/MPA.0b013e3181a20f9c. Pancreas. 2009. PMID: 19346993
-
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.Clin Cancer Res. 2001 Jan;7(1):158-67. Clin Cancer Res. 2001. PMID: 11205904
-
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.Exp Biol Med (Maywood). 2004 Jul;229(7):567-85. doi: 10.1177/153537020422900701. Exp Biol Med (Maywood). 2004. PMID: 15229351 Review.
-
Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1.Exp Biol Med (Maywood). 2009 Jun;234(6):639-50. doi: 10.3181/0810-RM-300. Epub 2009 Apr 9. Exp Biol Med (Maywood). 2009. PMID: 19359655
-
Mevalonate-suppressive dietary isoprenoids for bone health.J Nutr Biochem. 2012 Dec;23(12):1543-51. doi: 10.1016/j.jnutbio.2012.07.007. Epub 2012 Sep 13. J Nutr Biochem. 2012. PMID: 22981371 Review.
Cited by
-
Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review.Int J Mol Sci. 2016 Sep 22;17(10):1605. doi: 10.3390/ijms17101605. Int J Mol Sci. 2016. PMID: 27669218 Free PMC article. Review.
-
{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.Cancer Res. 2010 Nov 1;70(21):8695-705. doi: 10.1158/0008-5472.CAN-10-2318. Epub 2010 Sep 23. Cancer Res. 2010. PMID: 20864511 Free PMC article.
-
The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.Front Pharmacol. 2019 Jan 4;9:1515. doi: 10.3389/fphar.2018.01515. eCollection 2018. Front Pharmacol. 2019. PMID: 30662405 Free PMC article. Review.
-
Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells.Cancer Biol Ther. 2011 Oct 15;12(8):707-17. doi: 10.4161/cbt.12.8.16441. Epub 2011 Oct 15. Cancer Biol Ther. 2011. PMID: 21799303 Free PMC article.
-
Targeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: micro-computed tomography and biomechanical evaluation.PLoS One. 2014 Dec 19;9(12):e115595. doi: 10.1371/journal.pone.0115595. eCollection 2014. PLoS One. 2014. PMID: 25526611 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical